TRAXV
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued • NASDAQ
$22.51 ▲ -11.38% (+22.51)
TRAXV
First Tracks Biotherapeutics, Inc. Ordinary Shares When-IssuedNASDAQ • $22.51 ▲ -11.38% (+22.51)
Market Cap $782.20 M
52w High $26.80
52w Low $19.00
P/E 0
Volume 20.88K
Outstanding Shares 34.75M
Market Cap $782.20 M
52w High $26.80
52w Low $19.00
P/E 0
Volume 20.88K
Outstanding Shares 34.75M
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.
CEO
Daniel R. Faga
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public April 6, 2026
Full time employees 0
ETFs Holding This Stock
Summary
Total 5
Showing Top 3 of 5
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0